Major Shareholder Atlas Venture Files Intent to Sell $6.7M in Kymera Therapeutics Stock
KYMR has more than doubled off its 52-week low of $36.65 on elevated volume (5.7× avg).
Summary
A major institutional shareholder, Atlas Venture Opportunity Fund I, LP, filed a Form 144 to sell $6.72 million in Kymera Therapeutics stock, continuing a pattern of significant share distribution.
Key Events · Ownership and Investor Activity · KYMR
-
Intent to Sell Shares
Atlas Venture Opportunity Fund I, LP, a significant shareholder, filed a Form 144 to sell 67,329 shares of common stock, valued at approximately $6.72 million.
-
Ongoing Share Distribution
This filing is part of a broader pattern of share distribution by Atlas Venture entities, which have sold over $70 million in Kymera Therapeutics stock over the last three months.
Analysis · KYMR · Life Sciences
Atlas Venture Opportunity Fund I, LP, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell approximately $6.72 million worth of Kymera Therapeutics common stock. This filing is part of an ongoing pattern of distribution by Atlas Venture entities, which have collectively sold over $70 million in shares over the past three months. This continuous selling by a major investor can create sustained selling pressure on the stock.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.4% of the 1637 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYMR was trading at $115.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6B. The 52-week trading range was $36.65 to $130.05. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.